Bio-Rad Laboratories, Inc.
BIO
Rank in Stocks
#2176
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules,... Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Share Price
$352.89
Last synced: 2026-10-16
Market Cap
$9.44B
Change (1 day)
-3.34%
Change (1 year)
13.83%
Country
US
Trade Bio-Rad Laboratories, Inc. (BIO)
Category
Healthcare
Operating Margin for Bio-Rad Laboratories, Inc. (BIO)
Operating Margin as of October 2026 TTM: 9.08%
According to Bio-Rad Laboratories, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 9.08%. At the end of 2023 the company had an Operating Margin of 12.65%.
Operating Margin history for Bio-Rad Laboratories, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 9.08% | -13.36% |
| 2024 | 10.48% | -17.15% |
| 2023 | 12.65% | -26.54% |
| 2022 | 17.22% | 0.58% |
| 2021 | 17.12% | 3.44% |
| 2020 | 16.55% | 66.67% |
| 2019 | 9.93% | -309.49% |
| 2018 | -4.74% | -187.78% |
| 2017 | 5.40% | 110.12% |
| 2016 | 2.57% | -68.89% |
| 2015 | 8.26% | 19.71% |
| 2014 | 6.90% | -13.21% |
| 2013 | 7.95% | -37.70% |
| 2012 | 12.76% | -10.33% |
| 2011 | 14.23% | -3.46% |
| 2010 | 14.74% | 13.82% |
| 2009 | 12.95% | 24.88% |
| 2008 | 10.37% | 12.11% |
| 2007 | 9.25% | -19.35% |
| 2006 | 11.47% | 17.52% |
| 2005 | 9.76% | -2.30% |
| 2004 | 9.99% | -31.25% |
| 2003 | 14.53% | -5.59% |
| 2002 | 15.39% | 12.34% |
| 2001 | 13.70% | 48.91% |
| 2000 | 9.20% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 17.03% | -98.12% |
US
|
|
| 17.86% | -98.03% |
IE
|
|
| 22.03% | -97.57% |
US
|
|
| 21.46% | -97.64% |
US
|
|
| 0.00% | - |
DE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.